Vimarsana
Biggest News Aggregation in the World

Page 7 - Triple Negative News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Triple Negative. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Triple Negative Today - Breaking & Trending Today

Now Or Never to receive a one-night-only anniversary stream - Vimarsana News

Now Or Never to receive a one-night-only anniversary stream

Funds raised will benefit The Suzie Mackie Fellowship

Research: Drug shows improved results for triple-negative breast cancer - Vimarsana News

Research: Drug shows improved results for triple-negative breast cancer

According to Houston Methodist researchers who released results on a new combined therapy with the potential to improve outcomes for these hard-to-treat breast cancer patients, a drug used to treat cardiac failure has shown promising results in treating triple-negative breast cancer.

Repurposed drug shows improved results with combined therapy for triple-negative breast cancer: Study - Vimarsana News

Repurposed drug shows improved results with combined therapy for triple-negative breast cancer: Study

A drug used to treat cardiac failure has shown promising results in treating triple-negative breast cancer, according to Houston Methodist researchers who released results this week on a new combined therapy with the potential to improve outcomes for these hard-to-treat breast cancer patients.

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021 - Vimarsana News

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021

12.12.2021 - Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today presented positive data from its ongoing global Phase 2 clinical ... Seite 1

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021 - Vimarsana News

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021

- Expanded Phase 2 data set continues to provide compelling rationale for move to registrational clinical program - - Bomedemstat demonstrated durable clinical improvement in patients with ET who... | December 12, 2021